pentoxifylline has been researched along with Weight Loss in 8 studies
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentoxifylline therapy results in weight loss, improved liver function and histological changes in patients with NAFLD/NASH." | 8.90 | Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. ( Du, J; Li, YM; Ma, YY; Yu, CH, 2014) |
| "Cardiac cachexia was rapidly induced with monocrotaline in Sprague-Dawley rats." | 5.35 | Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. ( Booth, FW; Lees, SJ; Steffen, BT, 2008) |
| "Pentoxifylline therapy results in weight loss, improved liver function and histological changes in patients with NAFLD/NASH." | 4.90 | Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. ( Du, J; Li, YM; Ma, YY; Yu, CH, 2014) |
| "Nonalcoholic fatty liver disease is the most common cause of chronic liver disease in Western countries, and consists of a spectrum of histopathological changes that range in severity from simple steatosis to steatohepatitis to cirrhosis." | 2.50 | State of the art: treatment of nonalcoholic steatohepatitis. ( Loomba, R; Pearlman, M, 2014) |
| "Although it is easy to diagnose NAFLD, a liver biopsy is currently required to diagnose nonalcoholic steatohepatitis (NASH)." | 2.48 | Nonalcoholic fatty liver disease. ( Harrison, SA; Paredes, AH; Torres, DM, 2012) |
| "Cardiac cachexia was rapidly induced with monocrotaline in Sprague-Dawley rats." | 1.35 | Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. ( Booth, FW; Lees, SJ; Steffen, BT, 2008) |
| "Flurbiprofen co-treatment markedly attenuated these actions of pentoxifylline on nerve conduction and blood flow whereas NG-nitro-L-arginine was without effect." | 1.31 | Pentoxifylline effects on nerve conduction velocity and blood flow in diabetic rats. ( Cameron, NE; Cotter, MA; Flint, H, 2000) |
| "Severe weight loss is a common manifestation of advanced infection with the human immunodeficiency virus." | 1.29 | Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. ( Landman, D; Sarai, A; Sathe, SS, 1994) |
| " Pharmacokinetic characteristics of the drugs were similar except that HWA-285 produced lower concentrations in serum and A81-3138 showed a dose-dependent kinetics (longer half-life at a higher dose)." | 1.28 | Efficacy, toxicity, and pharmacokinetics of pentoxifylline and its analogs in experimental Staphylococcus aureus infections. ( Breaux, S; Krause, PJ; Maderazo, EG; Woronick, CL, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, J | 1 |
| Ma, YY | 1 |
| Yu, CH | 1 |
| Li, YM | 1 |
| Pearlman, M | 1 |
| Loomba, R | 1 |
| Steffen, BT | 1 |
| Lees, SJ | 1 |
| Booth, FW | 1 |
| Paredes, AH | 1 |
| Torres, DM | 1 |
| Harrison, SA | 1 |
| Landman, D | 1 |
| Sarai, A | 1 |
| Sathe, SS | 1 |
| Breuillé, D | 1 |
| Farge, MC | 1 |
| Rosé, F | 1 |
| Arnal, M | 1 |
| Attaix, D | 1 |
| Obled, C | 1 |
| Flint, H | 1 |
| Cotter, MA | 1 |
| Cameron, NE | 1 |
| Maderazo, EG | 1 |
| Breaux, S | 1 |
| Woronick, CL | 1 |
| Krause, PJ | 1 |
3 reviews available for pentoxifylline and Weight Loss
| Article | Year |
|---|---|
Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.
Topics: Biomarkers; Humans; Liver; Liver Function Tests; Non-alcoholic Fatty Liver Disease; Pentoxifylline; | 2014 |
State of the art: treatment of nonalcoholic steatohepatitis.
Topics: Antioxidants; Exercise; Humans; Hypoglycemic Agents; Life Style; Non-alcoholic Fatty Liver Disease; | 2014 |
Nonalcoholic fatty liver disease.
Topics: Antioxidants; Biomarkers; Cholagogues and Choleretics; Diabetes Complications; Fatty Acids, Omega-3; | 2012 |
5 other studies available for pentoxifylline and Weight Loss
| Article | Year |
|---|---|
Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia.
Topics: Animals; Anorexia; Blotting, Western; Body Weight; Cachexia; Eating; Enzyme-Linked Immunosorbent Ass | 2008 |
Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cachexia; Humans; Male; Middle Aged; Pentoxifylline; Pilo | 1994 |
Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis.
Topics: Animals; Eating; Escherichia coli Infections; Liver; Male; Muscle Proteins; Muscles; Pentoxifylline; | 1993 |
Pentoxifylline effects on nerve conduction velocity and blood flow in diabetic rats.
Topics: Animals; Blood Glucose; Cyclooxygenase Inhibitors; Diabetes Mellitus, Experimental; Flurbiprofen; Ma | 2000 |
Efficacy, toxicity, and pharmacokinetics of pentoxifylline and its analogs in experimental Staphylococcus aureus infections.
Topics: Animals; Animals, Newborn; Chromatography, High Pressure Liquid; Mice; Mice, Inbred C57BL; Microbial | 1990 |